Aurora Cannabis Inc. (ACB) stock analysis

Healthcare · Drug Manufacturers - Specialty & Generic

From the 40-F filed 2026-06-11

How it makes money

It generates revenue by producing and selling medical cannabis products to patients, with profitability driven by international market expansion and medical-specific distribution channels.

The company focuses on the medical cannabis sector, leveraging high-THC flower and other medical formats like pastilles. It serves specific patient needs through international subsidiaries, such as its operations in Australia and Germany.

Growth and profitability are heavily influenced by the company's ability to navigate complex medical regulatory environments and the successful distribution of its proprietary products through specialized medical networks.

What protects it: the moat

Management claims that its diverse portfolio of patient-specific products and its established international medical cannabis supply chains provide a competitive barrier.

The company emphasizes its commitment to providing consistent and reliable medical products to patients through specialized clinical channels, asserting that this focus on patient-specific care and physician prescription networks supports its market position.

What growth costs

It funds growth and maintains operations through recurring equity offerings, asset divestitures, and the strategic acquisition of international subsidiaries.

To sustain its business, the company actively manages its capital structure. This involves issuing shares to fund acquisitions, such as purchasing the remaining 90% equity interest of MedReleaf Australia, and liquidating non-core assets like the Aurora Sun Facility.

The company does not disclose specific recurring maintenance capital expenditures, focusing instead on debt repayment and targeted strategic investments.

What could damage it

Regulatory uncertainty in international markets can force the company to abandon agreements, potentially impairing its ability to reach target medical patient populations.

The business model relies on maintaining license status and regulatory approval in specific regions. If external factors or shifting regulations render existing agreements unviable, the company must exit, leading to lost investments and reduced access to key international markets.

About Aurora Cannabis Inc.

Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products. It also provides harvested cannabis, trim, cannabis oils, capsules, edibles, vaporizers, dried and fresh cannabis, cannabis plants, cannabis seeds, edible cannabis, cannabis extracts, flowers, vapes / inhalable extracts, edibles / pastilles, concentrates, and cannabis topicals; and patient counseling and outreach services. Its brand portfolio includes Aurora, Being, CanniMed, CraftPlant, Daily Special, Drift, Greybeard, IndiMed, MedReleaf, Pedanios, San Raf, Tasty's, Whistler, and WMMC. The company also engages in pharmacy activities. Aurora Cannabis Inc. was founded in 2013 and is headquartered in Edmonton, Canada.

Other companies in Drug Manufacturers - Specialty & Generic